News Releases

Feb 26, 2024 Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
AeriSeal System Shows Promise in Limiting Collateral Ventilation, Potentially Enabling a Greater Number of Severe COPD/Emphysema Patients to Benefit from Treatment with Zephyr ® Valves, a Minimally Invasive Treatment Option REDWOOD CITY, Calif. --(BUSINESS WIRE)--Feb.
Feb 21, 2024 Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023.
Feb 21, 2024 Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company’s President and Chief Executive Officer, effective
Feb 07, 2024 Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading
Print Page
Email Alerts
Contact IR
RSS Feeds